Lymphoma, Follicular | Marginal Zone B-Cell Lymphoma | Small Lymphocytic Lymphoma | CLL
Item
diagnosis of fl, mzl, sll, or cll (meeting international workshop on cll [iwcll] criteria, 2008) as documented by medical records and with histology based on criteria established by the world health organization
boolean
C0024301 (UMLS CUI [1])
C1367654 (UMLS CUI [2])
C0855095 (UMLS CUI [3])
C0023434 (UMLS CUI [4])
Follicular Lymphoma Ann Arbor lymphoma staging system
Item
fl grades 1, 2, or 3a
boolean
C0024301 (UMLS CUI [1,1])
C0432516 (UMLS CUI [1,2])
Small Lymphocytic Lymphoma | Absolute lymphocyte count
Item
sll with absolute lymphocyte count of < 5 x 10^9/l at initial diagnosis
boolean
C0855095 (UMLS CUI [1])
C3544087 (UMLS CUI [2])
Splenic Marginal Zone B-Cell Lymphoma | Nodal marginal zone B-cell lymphoma | Extranodal marginal zone B-cell lymphoma
Item
mzl (splenic, nodal, or extra-nodal)
boolean
C0349632 (UMLS CUI [1])
C0242647 (UMLS CUI [2])
C1955690 (UMLS CUI [3])
Prior Therapy Follicular Lymphoma | Prior Therapy CLL | Prior Therapy Small Lymphocytic Lymphoma | Prior Chemotherapy Quantity | Prior Immunotherapy Quantity
Item
prior treatment for fl or cll/sll with ≥ 1 prior chemotherapy-based or immunotherapy-based regimen with no approved therapies available
boolean
C1514463 (UMLS CUI [1,1])
C0024301 (UMLS CUI [1,2])
C1514463 (UMLS CUI [2,1])
C0023434 (UMLS CUI [2,2])
C1514463 (UMLS CUI [3,1])
C0855095 (UMLS CUI [3,2])
C1514457 (UMLS CUI [4,1])
C1265611 (UMLS CUI [4,2])
C1514461 (UMLS CUI [5,1])
C1265611 (UMLS CUI [5,2])
Lymphadenopathy Measurable Radiography | Malignant lymphoid neoplasm Extranodal Measurable Radiography
Item
presence of radiographically measurable lymphadenopathy or extra nodal lymphoid malignancy
boolean
C0497156 (UMLS CUI [1,1])
C1513040 (UMLS CUI [1,2])
C0034571 (UMLS CUI [1,3])
C0746336 (UMLS CUI [2,1])
C1517067 (UMLS CUI [2,2])
C1513040 (UMLS CUI [2,3])
C0034571 (UMLS CUI [2,4])
Cancer treatment | Toxic effects Resolved CTCAE Grades | Exception Alopecia CTCAE Grades | Exception Bone Marrow parameters CTCAE Grades
Item
all acute toxic effects of any prior antitumor therapy resolved to grade ≤1 before the start of study therapy (with the exception of alopecia [grade 1 or 2 permitted], or bone marrow parameters [any of grade 1, 2, or 3 permitted)
boolean
C0920425 (UMLS CUI [1])
C0600688 (UMLS CUI [2,1])
C1514893 (UMLS CUI [2,2])
C1516728 (UMLS CUI [2,3])
C1705847 (UMLS CUI [3,1])
C0002170 (UMLS CUI [3,2])
C1516728 (UMLS CUI [3,3])
C1705847 (UMLS CUI [4,1])
C0005953 (UMLS CUI [4,2])
C0449381 (UMLS CUI [4,3])
C1516728 (UMLS CUI [4,4])
ECOG performance status
Item
eastern cooperative oncology group (ecog) ≤ 2
boolean
C1520224 (UMLS CUI [1])
Informed Consent
Item
able to provide written informed consent
boolean
C0021430 (UMLS CUI [1])
Malignant lymphoid neoplasm | Exception Follicular Lymphoma | Exception Marginal Zone B-Cell Lymphoma | Exception Small Lymphocytic Lymphoma | Exception CLL
Item
history of lymphoid malignancy other than fl, mzl, sll, or cll
boolean
C0746336 (UMLS CUI [1])
C1705847 (UMLS CUI [2,1])
C0024301 (UMLS CUI [2,2])
C1705847 (UMLS CUI [3,1])
C1367654 (UMLS CUI [3,2])
C1705847 (UMLS CUI [4,1])
C0855095 (UMLS CUI [4,2])
C1705847 (UMLS CUI [5,1])
C0023434 (UMLS CUI [5,2])
MYELODYSPLASTIC SYNDROME
Item
history of myelodysplastic syndrome
boolean
C3463824 (UMLS CUI [1])
Malignant Neoplasms | Exception Malignant lymphoid neoplasm | Exception Basal cell carcinoma Treated | Exception Squamous cell carcinoma of skin Treated | Exception Carcinoma in situ of uterine cervix | Exception Superficial carcinoma of urinary bladder | Exception Prostate carcinoma Asymptomatic | Exception Prostate carcinoma Without Neoplasm Metastasis | Exception Prostate carcinoma Requirement Hormone Therapy | Exception Prostate carcinoma Prostate specific antigen normal | Exception Cancer Other In complete remission Duration
Item
history of a non-lymphoid malignancy except for the following: adequately treated local basal cell or squamous cell carcinoma of the skin, cervical carcinoma in situ, superficial bladder cancer, asymptomatic prostate cancer without known metastatic disease and with no requirement for therapy or requiring only hormonal therapy and with normal prostate-specific antigen for ≥ 1 year prior to start of study therapy, or any other cancer that has been in complete remission for ≥ 5 years
boolean
C0006826 (UMLS CUI [1])
C1705847 (UMLS CUI [2,1])
C0746336 (UMLS CUI [2,2])
C1705847 (UMLS CUI [3,1])
C0007117 (UMLS CUI [3,2])
C1522326 (UMLS CUI [3,3])
C1705847 (UMLS CUI [4,1])
C0553723 (UMLS CUI [4,2])
C1522326 (UMLS CUI [4,3])
C1705847 (UMLS CUI [5,1])
C0851140 (UMLS CUI [5,2])
C1705847 (UMLS CUI [6,1])
C1336527 (UMLS CUI [6,2])
C1705847 (UMLS CUI [7,1])
C0600139 (UMLS CUI [7,2])
C0231221 (UMLS CUI [7,3])
C1705847 (UMLS CUI [8,1])
C0600139 (UMLS CUI [8,2])
C0332288 (UMLS CUI [8,3])
C0027627 (UMLS CUI [8,4])
C1705847 (UMLS CUI [9,1])
C0600139 (UMLS CUI [9,2])
C1514873 (UMLS CUI [9,3])
C0279025 (UMLS CUI [9,4])
C1705847 (UMLS CUI [10,1])
C0600139 (UMLS CUI [10,2])
C0580554 (UMLS CUI [10,3])
C1705847 (UMLS CUI [11,1])
C1707251 (UMLS CUI [11,2])
C0677874 (UMLS CUI [11,3])
C0449238 (UMLS CUI [11,4])
Systemic bacterial infection | Systemic mycosis | Systemic viral infection
Item
evidence of ongoing systemic bacterial, fungal, or viral infection at the time of start of study therapy
boolean
C4285778 (UMLS CUI [1])
C0553576 (UMLS CUI [2])
C4285789 (UMLS CUI [3])
Drug-induced pneumonitis
Item
ongoing drug-induced pneumonitis
boolean
C1960026 (UMLS CUI [1])
Inflammatory Bowel Disease
Item
ongoing inflammatory bowel disease
boolean
C0021390 (UMLS CUI [1])
Bone Marrow Stem Cell Transplantation Allogeneic | Solid organ transplant
Item
history of prior allogeneic bone marrow progenitor cell or solid organ transplantation
boolean
C0842093 (UMLS CUI [1,1])
C1515895 (UMLS CUI [1,2])
C0730400 (UMLS CUI [2])
AKT Inhibitor | IBTK | Janus kinase inhibitor | mTOR Inhibitor | Phosphatidylinositide 3-Kinase Inhibitor | SYK Inhibitor
Item
history of prior therapy with any inhibitor of serine/threonine kinase (akt), bruton tyrosine kinase (btk), janus kinase (jak), mammalian target of rapamycin (mtor), phosphatidylinositol 3-kinase (pi3k), or spleen tyrosine kinase (syk)
boolean
C0812228 (UMLS CUI [1,1])
C1999216 (UMLS CUI [1,2])
C1425132 (UMLS CUI [2])
C3854325 (UMLS CUI [3])
C2746052 (UMLS CUI [4])
C1519050 (UMLS CUI [5])
C1335892 (UMLS CUI [6,1])
C1999216 (UMLS CUI [6,2])
Therapeutic immunosuppression | CORTICOSTEROIDS FOR SYSTEMIC USE Malignant lymphoid neoplasm
Item
ongoing immunosuppressive therapy, including systemic corticosteroids for treatment of lymphoid malignancy
boolean
C0021079 (UMLS CUI [1])
C3653708 (UMLS CUI [2,1])
C0746336 (UMLS CUI [2,2])